Pacific Biosciences of California, Inc. (PACB)
USD 1.85
(-6.09%)
USD 1.85
(-6.09%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -266.54 Million | -263.21 Million | -111.18 Million | 19.5 Million | -78.31 Million | -66.43 Million |
| Net Income | -306.73 Million | -314.24 Million | -181.22 Million | 29.4 Million | -84.13 Million | -102.56 Million |
| Depreciation & Amortization | 32.69 Million | 17.31 Million | 11.58 Million | 9.3 Million | 9.94 Million | 7.21 Million |
| Deferred income taxes | -11.42 Million | - | -93.64 Million | -107 Thousand | -735 Thousand | -925 Thousand |
| Stock-based compensation | 72.11 Million | 78.61 Million | 80.72 Million | 17.53 Million | 16.4 Million | 23.15 Million |
| Change in working capital | -58.95 Million | -53.97 Million | 21 Million | -2.75 Million | -3 Million | 5.66 Million |
| Other non-cash items | 5.75 Million | 9.07 Million | 57.74 Million | -33.87 Million | -16.78 Million | 1.02 Million |
| Investing Cash Flow | 4.6 Million | 116.08 Million | -678.53 Million | -219.32 Million | 62.04 Million | -38.41 Million |
| Investments in PPE | -8.84 Million | -16.92 Million | -5.93 Million | -1.03 Million | -2.83 Million | -1.85 Million |
| Acquisitions | -102 Thousand | 179 Thousand | -319.79 Million | 218.28 Million | -64.88 Million | - |
| Investment purchases | -756.56 Million | -442.78 Million | -988.04 Million | -373.28 Million | -57.72 Million | -122.18 Million |
| Sales/Maturities of investments | 770.11 Million | 575.8 Million | 635.23 Million | 155 Million | 122.61 Million | 85.62 Million |
| Other Investing Activities | 13.54 Million | -179 Thousand | -352.8 Million | -218.28 Million | 64.88 Million | -36.56 Million |
| Financing Cash Flow | 116.26 Million | 9.62 Million | 1.16 Billion | 251.83 Million | 26.54 Million | 107.18 Million |
| Debt repayment | -1.84 Million | -1.6 Million | -895.17 Million | -16 Million | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 204.51 Million | 11.23 Million | 326.65 Million | 187.47 Million | 8.54 Million | 97.53 Million |
| Other Financing Activities | -86.41 Million | 11.23 Million | -52.24 Million | 80.36 Million | 18 Million | 9.65 Million |
| Accounts receivables | -17.82 Million | 5.45 Million | -7.16 Million | -1.6 Million | -6.67 Million | 4.83 Million |
| Accounts payables | 206 Thousand | 1.02 Million | 14.86 Million | -789 Thousand | 1.71 Million | -2.23 Million |
| Inventory | -13.84 Million | -33.9 Million | -12.43 Million | -1.09 Million | 3.91 Million | 3.62 Million |
| Other working capital | -27.49 Million | -26.54 Million | 25.73 Million | 729 Thousand | -1.96 Million | -557 Thousand |
| Cash at beginning of period | 325.38 Million | 465.81 Million | 85.94 Million | 33.92 Million | 23.34 Million | 21 Million |
| Cash at end of period | 180.21 Million | 328.31 Million | 465.81 Million | 85.94 Million | 33.62 Million | 23.34 Million |
| Capital Expenditure | -8.84 Million | -16.92 Million | -5.93 Million | -1.03 Million | -2.83 Million | -1.85 Million |
| Effect of forex changes on cash | 500 Thousand | - | - | - | - | - |
| Net cash flow / Change in cash | -145.17 Million | -137.5 Million | 379.87 Million | 52.02 Million | 10.28 Million | 2.33 Million |
| Free Cash Flow | -275.39 Million | -280.14 Million | -117.11 Million | 18.46 Million | -81.14 Million | -68.28 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -173.31 Million | -78.17 Million | -82.01 Million | -306.73 Million | -66.86 Million | -69.83 Million |
| Depreciation & Amortization | 14.28 Million | 12.01 Million | 17.85 Million | 32.69 Million | 5.45 Million | 4.86 Million |
| Deferred income taxes | - | - | -718 Thousand | -11.42 Million | -14.33 Million | -1.3 Million |
| Stock-based compensation | 17.21 Million | 19.52 Million | 16.58 Million | 72.11 Million | 19.69 Million | 17.89 Million |
| Change in working capital | -6.32 Million | -25.34 Million | -7.74 Million | -58.95 Million | -12.59 Million | 4.5 Million |
| Other non-cash items | 150.15 Million | 38.57 Million | -1.57 Million | 5.75 Million | 3.46 Million | 2.13 Million |
| Investing Cash Flow | 76.83 Million | -34.13 Million | -66.57 Million | 4.6 Million | 242.32 Million | -98.59 Million |
| Investments in PPE | -1.47 Million | -3.87 Million | -2.02 Million | -8.84 Million | -830 Thousand | -2.26 Million |
| Acquisitions | - | - | - | -102 Thousand | -102 Thousand | 96.32 Million |
| Investment purchases | -111.65 Million | -191.9 Million | -202.81 Million | -756.56 Million | -76.86 Million | -243.58 Million |
| Sales/Maturities of investments | 189.97 Million | 161.65 Million | 138.26 Million | 770.11 Million | 320.12 Million | 147.26 Million |
| Other Investing Activities | 78.31 Million | -30.25 Million | -64.55 Million | 13.54 Million | 243.25 Million | -96.32 Million |
| Financing Cash Flow | -152 Thousand | 6.55 Million | -81.55 Million | 116.26 Million | -781 Thousand | -4.71 Million |
| Debt repayment | -152 Thousand | -338 Thousand | -445 Thousand | -1.84 Million | -486 Thousand | -465 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 2.58 Million | 6.89 Million | 936 Thousand | 204.51 Million | 4.56 Million | 2.58 Million |
| Other Financing Activities | - | 6.89 Million | -82.04 Million | -86.41 Million | -4.85 Million | -6.83 Million |
| Accounts receivables | -2.11 Million | 6.29 Million | -6.12 Million | -17.82 Million | -6.45 Million | 5.55 Million |
| Accounts payables | -3.25 Million | 6.64 Million | -1.5 Million | 206 Thousand | -447 Thousand | 8.07 Million |
| Inventory | -5.11 Million | -11.65 Million | 9 Million | -13.84 Million | -3.14 Million | -6.38 Million |
| Other working capital | 4.14 Million | -26.62 Million | -9.11 Million | -27.49 Million | -2.55 Million | -2.74 Million |
| Cash at beginning of period | 76.94 Million | 180.21 Million | 385.94 Million | 325.38 Million | 212 Million | 353.83 Million |
| Cash at end of period | 99.86 Million | 76.94 Million | 180.21 Million | 180.21 Million | 388.37 Million | 212 Million |
| Capital Expenditure | -1.47 Million | -3.87 Million | -2.02 Million | -8.84 Million | -830 Thousand | -2.26 Million |
| Effect of forex changes on cash | - | - | - | 500 Thousand | - | 3.22 Million |
| Net cash flow / Change in cash | 22.92 Million | -103.26 Million | -205.73 Million | -145.17 Million | 176.36 Million | -141.82 Million |
| Free Cash Flow | -55.74 Million | -79.56 Million | -59.63 Million | -275.39 Million | -66.01 Million | -44 Million |
8942
MPL
STRR
MANVF
002681
NMDC